CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Diffuse Large B Cell Lymphoma (DLBCL)
- Follicular Lymphoma ( FL)
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma (MZL)
- Primary Mediastinal Large B Cell Lymphoma
- Relapsed/Refractory B-cell Lymphomas
- Small Lymphocytic Lymphoma (SLL)
- Transformed Follicular Lymphoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
CLBR001 + SWI019 is a two-component therapy comprising an autologous chimeric antigen receptor T (CAR-T) cell product (CLBR001, the switchable CAR-T cell (sCAR-T)) and an anti-CD19 (cluster of differentiation antigen 19) antibody (SWI019, the switch, a biologic). In combination, SWI019 acts as an ad...
CLBR001 + SWI019 is a two-component therapy comprising an autologous chimeric antigen receptor T (CAR-T) cell product (CLBR001, the switchable CAR-T cell (sCAR-T)) and an anti-CD19 (cluster of differentiation antigen 19) antibody (SWI019, the switch, a biologic). In combination, SWI019 acts as an adapter molecule that controls the activity of the CLBR001 CAR-T cell product.
Tracking Information
- NCT #
- NCT04450069
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Carolyn Mulroney, MD University of California, San Diego
Get Well Soon